Switching from Combivir[CBV] (AZT/3TC) to Truvada [TVD] (Tenofovir DF/FTC) Maintains Viral Suppression, Prevents and Reverses Limb Fat Loss, and Improves Biochemical Parameters: Results of a 48 Week Randomised Study by Martin Fisher given during the 11th European AIDS Conference / EACS powered by - MULTIWEBCAST

11th European AIDS Conference / EACS

LIST OF PRESENTATIONS

OTHER WEBCASTS

Webcasted Presentation

BROWSE:

Martin Fisher

United Kingdom

Switching from Combivir[CBV] (AZT/3TC) to Truvada [TVD] (Tenofovir DF/FTC) Maintains Viral Suppression, Prevents and Reverses Limb Fat Loss, and Improves Biochemical Parameters: Results of a 48 Week Randomised Study

English

2007-10-25

PRESENTATION

16 slide(s)

Extra Features Available

SLIDE LIBRARY

Disclosure

Gilead Sciences Study, Granta Park, Abington, CAMBS CB21 GGT UK

Disclaimer ^{AMENDED ON January 29, 2009} | Close This Window | Technical Support

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.

Search’n Build™ Search presentations by keyword and instantly build your own highlight of the conference!

Search’n Build™
Search presentations by keyword and instantly build your own highlight of the conference!